Loading clinical trials...
Loading clinical trials...
TTCC-2022-02: A Phase II, Multicenter, Randomized Study of Cetuximab Plus/ Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)
Conditions
Interventions
Cetuximab
Paclitaxel
Locations
11
Spain
Instituto Catalán de Oncología - Hospital Duran i Reynals
Barcelona, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla (Santander)
Santander, Cantabria, Spain
Centro Oncológico de Galicia (La Coruña)
A Coruña, La Coruña, Spain
Hospital Clínico San Carlos
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre (Madrid)
Madrid, Madrid, Spain
Hospital Infanta Leonor (Madrid)
Vallecas, Madrid, Spain
Start Date
June 18, 2025
Primary Completion Date
October 1, 2028
Completion Date
October 1, 2028
Last Updated
August 21, 2025
Marisa Duran Senior Clinical research proyect manager (TTCC)
CONTACT
0034690756714mduran@ttccgrupo.comLead Sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions